Orient EuroPharma Co (4120) Fair Value & Analysis
Healthcare · TW · Market cap 4.0B TWD
Fair value as of: Jul 9, 2026
From 3 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from 326.15 TWD to 12.57 TWD (−96.1%) since Jun 24, 2026. Share price −0.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 43.35 TWD – 56.47 TWD · fair‑value band 11.41 TWD – 14.36 TWD · the 45.55 TWD price screens above the 12.57 TWD fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Orient EuroPharma Co (4120) currently trades at 45.55 TWD, while our model-based Fair Value estimate is 12.57 TWD — implying the stock looks roughly 72.4% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Orient EuroPharma Co generated revenue of 4.6B TWD at a net margin of -9.6%. Revenue declined 0.5% year over year. It earns a return on equity of -5.4%. Net debt stands at 986M TWD. Fundamentals as of Jul 9, 2026
Our scenario range runs from 11.41 TWD (bear case) to 14.36 TWD (bull case); at 45.55 TWD, the current price sits above that range. The share trades about 23% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -72%, 4120 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Orient EuroPharma Co reported revenue of 4.6B TWD in FY2025 versus 4.8B TWD in FY2021, a compound −0.9%/yr. Reported net income was −567M TWD in FY2025.
Is 4120 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Orient EuroPharma Co (4120) undervalued?
What is the fair value of 4120?
What is the quality score of 4120?
What is the revenue of Orient EuroPharma Co (4120)?
What is the net profit margin of 4120?
Does Orient EuroPharma Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.